NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free EDIT Stock Alerts $5.06 -0.43 (-7.83%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$5.03▼$5.4950-Day Range$5.04▼$7.0152-Week Range$4.91▼$11.69Volume3.33 million shsAverage Volume1.86 million shsMarket Capitalization$416.13 millionP/E RatioN/ADividend YieldN/APrice Target$12.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Editas Medicine alerts: Email Address Editas Medicine MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside154.9% Upside$12.90 Price TargetShort InterestBearish26.78% of Shares Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.75Based on 9 Articles This WeekInsider TradingAcquiring Shares$253,800 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.70) to ($2.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.58 out of 5 starsMedical Sector250th out of 915 stocksBiological Products, Except Diagnostic Industry32nd out of 152 stocks 3.2 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 4 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageEditas Medicine has only been the subject of 4 research reports in the past 90 days.Read more about Editas Medicine's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted26.78% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Editas Medicine has recently increased by 6.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 71.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.78. Previous Next 2.6 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Editas Medicine this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat Follows17 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 143% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have bought 263.29% more of their company's stock than they have sold. Specifically, they have bought $253,800.00 in company stock and sold $69,861.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Editas Medicine's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to grow in the coming year, from ($2.70) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Editas Medicine's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Editas Medicine Stock (NASDAQ:EDIT)Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Read More EDIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EDIT Stock News HeadlinesJune 7, 2024 | insidertrades.comGilmore Neil O'neill Sells 12,191 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) StockMay 15, 2024 | insidertrades.comEditas Medicine, Inc. (NASDAQ:EDIT) Director Jessica Hopfield Acquires 45,000 SharesJune 14 at 3:01 AM | globenewswire.comEditas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual CongressJune 14 at 3:00 AM | globenewswire.comEditas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual CongressJune 13 at 2:28 AM | americanbankingnews.comBrokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $13.27June 9, 2024 | americanbankingnews.comInsider Selling: Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $67,050.50 in StockMay 28, 2024 | finance.yahoo.comAzzur Cleanrooms on Demand™ Grand Opening in Devens, MA Brings Together Local, State and Life Sciences LeadersMay 23, 2024 | msn.comUnique gene editing drug could treat genetic blindness, but how it compares to existing therapiesMay 15, 2024 | seekingalpha.comEditas Medicine: Promising Milestone Achieved But Be PatientMay 14, 2024 | finance.yahoo.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)May 14, 2024 | globenewswire.comEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in JuneMay 12, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth PotentialMay 10, 2024 | markets.businessinsider.comEditas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal PrudenceMay 10, 2024 | globenewswire.comEditas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual MeetingMay 9, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | fool.com1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?May 9, 2024 | markets.businessinsider.comEditas Medicine’s Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy RatingMay 9, 2024 | markets.businessinsider.comBuy Rating for Editas Medicine: Promising Trials and Solid Financial Footing Propel Growth OutlookMay 9, 2024 | finance.yahoo.comEditas Medicine First Quarter 2024 Earnings: Misses ExpectationsMay 8, 2024 | washingtonpost.comEditas: Q1 Earnings SnapshotMay 8, 2024 | investorplace.comEDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comEditas Medicine Announces First Quarter 2024 Results and Business UpdatesMay 7, 2024 | msn.comGene Editing Improves Vision in Rare and Devastating Retinal DisorderMay 7, 2024 | msn.comEditas Medicine Q1 2024 Earnings PreviewSee More Headlines Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/15/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees265Year FoundedN/APrice Target and Rating Average Stock Price Target$12.90 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+154.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,220,000.00 Net Margins-239.36% Pretax Margin-239.36% Return on Equity-47.34% Return on Assets-33.46% Debt Debt-to-Equity RatioN/A Current Ratio4.60 Quick Ratio4.60 Sales & Book Value Annual Sales$78.12 million Price / Sales5.33 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book1.19Miscellaneous Outstanding Shares82,240,000Free Float80,675,000Market Cap$416.13 million OptionableOptionable Beta2.06 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Gilmore O'Neill M.D. (Age 60)President, CEO & Director Comp: $1.04MMr. Erick J. Lucera C.F.A. (Age 56)CPA, CFO & Executive VP Comp: $911.46kDr. Linda C. Burkly Ph.D. (Age 67)Executive VP & Chief Scientific Officer Comp: $522.44kDr. Baisong Mei M.D. (Age 60)Ph.D., Executive VP & Chief Medical Officer Comp: $654.9kDr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D. (Age 70)Co-Founder & Scientific Advisory Board Member More ExecutivesKey CompetitorsAdverum BiotechnologiesNASDAQ:ADVMCellectisNASDAQ:CLLSSangamo TherapeuticsNASDAQ:SGMObluebird bioNASDAQ:BLUEPrecision BioSciencesNASDAQ:DTILView All CompetitorsInsiders & InstitutionsGilmore Neil O'neillSold 12,191 sharesTotal: $67,050.50 ($5.50/share)Baisong MeiSold 511 sharesTotal: $2,810.50 ($5.50/share)Virtu Financial LLCSold 33,425 shares on 5/20/2024Ownership: 0.049%Walleye Trading LLCSold 100 shares on 5/17/2024Ownership: 0.000%Kennedy Capital Management LLCBought 133,214 shares on 5/16/2024Ownership: 0.162%View All Insider TransactionsView All Institutional Transactions EDIT Stock Analysis - Frequently Asked Questions Should I buy or sell Editas Medicine stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares. View EDIT analyst ratings or view top-rated stocks. What is Editas Medicine's stock price target for 2024? 10 Wall Street research analysts have issued 12-month target prices for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $20.00. On average, they expect the company's share price to reach $12.90 in the next year. This suggests a possible upside of 154.9% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts. How have EDIT shares performed in 2024? Editas Medicine's stock was trading at $10.13 at the start of the year. Since then, EDIT shares have decreased by 50.0% and is now trading at $5.06. View the best growth stocks for 2024 here. Are investors shorting Editas Medicine? Editas Medicine saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 22,020,000 shares, an increase of 6.1% from the May 15th total of 20,760,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the days-to-cover ratio is currently 11.7 days. View Editas Medicine's Short Interest. When is Editas Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our EDIT earnings forecast. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.13. The company earned $1.10 million during the quarter, compared to analyst estimates of $11.14 million. Editas Medicine had a negative trailing twelve-month return on equity of 47.34% and a negative net margin of 239.36%. The firm's quarterly revenue was down 88.9% compared to the same quarter last year. During the same period last year, the business earned ($0.71) earnings per share. What ETFs hold Editas Medicine's stock? ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Horizon Kinetics Medical ETF (MEDX), Global X Genomics & Biotechnology ETF (GNOM) and AXS Green Alpha ETF (NXTE).iShares Genomics Immunology and Healthcare ETF (IDNA). What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.40%), Mirae Asset Global Investments Co. Ltd. (0.38%), Susquehanna Portfolio Strategies LLC (0.22%), Los Angeles Capital Management LLC (0.18%), Kennedy Capital Management LLC (0.16%) and Jacobs Levy Equity Management Inc. (0.14%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Gilmore Neil O'neill, James C Mullen, Jessica Hopfield, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EDIT) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
